Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (71-80 of 146) with videos related to

Pageof 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
Nature Communications|June 13, 2019
Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channelsXingya Li, Huacheng Zhang, Peiyao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II StudyCaicun Zhou, Xingya Li, Qiming Wang, et al.
Experimental Hematology & Oncology|June 9, 2023
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trialsShiqi Mao, Shuo Yang, Xinyu Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2024
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical TrialYing Cheng, Yun Fan, Yanqiu Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 StudyYuankai Shi, Xingsheng Hu, Xingya Li, et al.
BMJ (Clinical Research Ed.)|June 5, 2025
Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trialWenfeng Fang, Xingya Li, Qiming Wang, et al.
Cancer Medicine|November 7, 2023
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III studyLikun Chen, Jose David Gomez Rangel, Timucin Cil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 14, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50Mark A Socinski, Martin Reck, Luis Paz-Ares, et al.
Thoracic Cancer|May 17, 2022
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional studyBo Zhang, Xingya Li, Zhiyong Ma, et al.
Pageof 15

Showing results (71-80 of 146) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
Nature Communications|June 13, 2019
Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channelsXingya Li, Huacheng Zhang, Peiyao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II StudyCaicun Zhou, Xingya Li, Qiming Wang, et al.
Experimental Hematology & Oncology|June 9, 2023
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trialsShiqi Mao, Shuo Yang, Xinyu Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2024
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical TrialYing Cheng, Yun Fan, Yanqiu Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 StudyYuankai Shi, Xingsheng Hu, Xingya Li, et al.
BMJ (Clinical Research Ed.)|June 5, 2025
Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trialWenfeng Fang, Xingya Li, Qiming Wang, et al.
Cancer Medicine|November 7, 2023
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III studyLikun Chen, Jose David Gomez Rangel, Timucin Cil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 14, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50Mark A Socinski, Martin Reck, Luis Paz-Ares, et al.
Thoracic Cancer|May 17, 2022
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional studyBo Zhang, Xingya Li, Zhiyong Ma, et al.
Pageof 15